FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...

Antimicrobial resistance and ecological disruption caused by broad-spectrum disinfectants have created an urgent need for ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...

Detailed price information for Armata Pharmaceuticals Inc (ARMP-A) from The Globe and Mail including charting and trades.

Bacteria from cows has shown "promising" results in treating hospital superbugs. The farmyard favorites carry a microbe that ...

Researchers have developed a sunlight-activated nanospray that can rapidly kill drug-resistant bacteria, stop bleeding and relieve pain, significantly accelerating the healing of infected diabetic ...

Experts warn that antibiotic misuse is fueling drug-resistant infections like gonorrhoea and staph, making them harder to ...

A new study reveals over 70% of staph infections in Nigeria are resistant to common antibiotics, a major public health ...

Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study ...

The African health organisation said that the study analysed more than 187,000 laboratory test results from 205 laboratories ...

After two dialysis patients died at a Kerala government hospital, concerns mount over infection and mortality risks in people ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...